Table 1.
Nanotherapies applied to antagonize angiogenesis in HNSCC.
| Nanocarriers | Agent | Name | Mechanism of action | Ref |
|---|---|---|---|---|
| Polymer based nanoparticles | Paclitaxel | PTX-NPs | Decreasing angiogenesis markers (Factor VIII, CD31, and CD34) | (26) |
| Gold Nanoparticles | Quinacrine | QAuNP | Modulation the cytokine profile in TME via p53/p21 signaling pathway | (38) |
| Liposomes | VEGF siRNA | LCP-NPs | siRNA-mediated VEGF gene silencing | (39) |
| Gold Nanoparticles | hyperthermia | GNR | Improved endocytosis of oncolytic Ad, transgene expression, viral replication | (40) |
| Peptide conjugated nanoparticles | Paclitaxel | GD16-PTX-NP | Target the angiogenic marker Dll4 | (41) |
| Polymer based nanoparticles | Resveratrol | Res-Nano | Decreased of angiogenic markers (MMPs, iNOS, VEGF-A, etc.) | (42) |